Information Provided By: 
Fly News Breaks for March 13, 2017
TGTX
Mar 13, 2017 | 07:07 EDT
SunTrust analyst Yatin Suneja says that the data on TG's CD20 antibody, TG-1101, was "highly positive." The analyst expects additional data on the drug due out in June to support its approval, and he thinks that the company has multiple potential positive turning points over the next 6-18 months. He raised his price target on the shares to $28 from $26 and keeps a Buy rating.
News For TGTX From the Last 2 Days
There are no results for your query TGTX
